Post by eleva

Join us at the Antibody Engineering & Therapeutics Europe in Basel on May 27–29! Our Director Business Development Jana Gross will be on site to discuss how Eleva is advancing biologic therapeutics for patients with high unmet medical needs. Our pipeline includes Factor H (CPV-104), a novel complement regulator being developed for a broad range of complement-mediated diseases, including C3G, dry AMD, and other renal disorders, as well as aGal (RPV-001), a promising enzyme replacement therapy for Fabry disease. Interested in learning more or exploring partnering opportunities? Let’s connect in Basel! #Biologics #Complement #FabryDisease #DrugDevelopment